122 related articles for article (PubMed ID: 1628372)
1. Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion.
Khayat D; Borel C; Azab M; Paraisot D; Malaurie E; Bouloux C; Weil M
Cancer Chemother Pharmacol; 1992; 30(3):226-8. PubMed ID: 1628372
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of retelliptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule.
Kattan J; Durand M; Droz JP; Mahjoubi M; Marino JP; Azab M
Am J Clin Oncol; 1994 Jun; 17(3):242-5. PubMed ID: 8192111
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of N-methylformamide (NMF, NSC 3051).
O'Dwyer PJ; Donehower M; Sigman LM; Fortner CL; Aisner J; Van Echo DA
J Clin Oncol; 1985 Jun; 3(6):853-7. PubMed ID: 4009219
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of elliptinium (2-N-methyl-9-hydroxyellipticinium).
Einzig AI; Gralla RJ; Leyland-Jones BR; Kelsen DP; Cibas I; Lewis E; Greenberg E
Cancer Invest; 1985; 3(3):235-41. PubMed ID: 4005651
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule.
Dodion P; Rozencweig M; Nicaise C; Piccart M; Cumps E; Crespeigne N; Kisner D; Kenis Y
Eur J Cancer Clin Oncol; 1982 Jun; 18(6):519-22. PubMed ID: 6889528
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
8. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
Calvert AH; Alison DL; Harland SJ; Robinson BA; Jackman AL; Jones TR; Newell DR; Siddik ZH; Wiltshaw E; McElwain TJ
J Clin Oncol; 1986 Aug; 4(8):1245-52. PubMed ID: 3734849
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.
Vogel CL; Gorowski E; Davila E; Eisenberger M; Kosinski J; Agarwal RP; Savaraj N
Invest New Drugs; 1987; 5(2):187-98. PubMed ID: 3115912
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.
O'Dwyer PJ; Laub PB; DeMaria D; Qian M; Reilly D; Giantonio B; Johnston AL; Wu EY; Bauman L; Clendeninn NJ; Gallo JM
Clin Cancer Res; 1996 Oct; 2(10):1685-92. PubMed ID: 9816117
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
Bailey H; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Grem JL; Spriggs DR
Cancer Chemother Pharmacol; 1992; 30(4):297-302. PubMed ID: 1643698
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
[TBL] [Abstract][Full Text] [Related]
13. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of high-dose diaziquone and autologous bone marrow transplantation: an Illinois Cancer Council study.
Stiff PJ; McKenzie RS; Potempa LD; Albain K; Koch D; Braud E; Bansal VK; Weidner MK; Lanzotti VJ; Chun HG
J Clin Oncol; 1991 Aug; 9(8):1487-94. PubMed ID: 2072148
[TBL] [Abstract][Full Text] [Related]
16. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
